SCHEMBL5947986

SCHEMBL5947986

c1ccc(Oc2cccc(CNCCc3ccc4ccccc4c3)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 7/20 0.58
▸ KDM4E B2RXH2 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ HTT P42858 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ LTA4H P09960 1/20 0.55
▸ EPHX2 P34913 1/20 0.55
▸ MC4R P32245 2/20 0.54
▸ MC5R P33032 2/20 0.54
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA4 P22748 1/20 0.53
▸ ROCK1 Q13464 1/20 0.53
▸ MC3R P41968 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ HTR2A P28223 1/20 0.50
▸ OPRM1 P35372 1/20 0.49
▸ OPRD1 P41143 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947260 0.88 BCHE (0.68) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947718 0.88 BCHE (0.72) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL22495340 0.85 GAA (0.63) BCHEKDM4EALDH1A1LTA4HEPHX2
SCHEMBL5947549 0.84 BCHE (0.76) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947298 0.84 CYP1A2 (0.52) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947179 0.84 BCHE (0.56) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947593 0.83 LTA4H (0.79) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947564 0.83 BCHE (0.62) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947437 0.83 BCHE (0.62) BCHEKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL5947283 0.83 BCHE (0.58) BCHEKDM4EALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B BCHE 763/4885KDM4E 1970/4885ALDH1A1 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback